Consequently, ICIs such as ipilimumab (anti-CTLA-4) [26] and anti-PD1 antibodies such as pembrolizumab and nivolumab (PD-1 inhibitors) [27] have been studied either as monotherapy or in combination to treat metastatic prostate cancer. The gene discussed is PDCD1; the disease is metastatic prostate carcinoma.